Abiopharma

Evolve Capital’s Equity Research – Near Term Performance Likely to Remain Subdued Before Modest Recovery

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Harnessing Human Potential to Power Vaccine Innovation

Gamescom 2025 Recap: Biggest Announcements and Highlights

AI in Game Design: Smarter NPCs, Dynamic Storytelling, and Procedural Worlds

NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit with the Schall Law Firm

NASDAQ symbol attribute type Security_Name was changed. Previous value: Connect Biopharma Holdings Limited - American Depositary Shares. New value: Connect Biopharma Holdings Limited - Ordinary Shares.

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

Smith+Nephew PLC Notification

3 SEPTEMBRE 2025

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

New Form SCHEDULE 13D - Shattuck Labs, Inc. Filed: 2025-09-02 AccNo: 0000947871-25-000841 Size: 30 KB

Director ORBIMED ADVISORS LLC 🟢 acquired 36.9M shares (4 derivative) of Shattuck Labs, Inc. (STTK) at $1.08 ($25.5M) Transaction Date: Aug 25, 2025 | Filing ID: 000840